Compare Ambarella Inc (AMBA) vs Medtronic PLC (MDT) Price & Performance

Ambarella (AMBA) trades at $77.30, down 1.38% on the day, with a bullish technical setup supported by moving averages and key resistance at $81. The company reported three consecutive quarterly EPS beats, with Q1 2027 earnings of $0.11 meeting estimates, while revenue grew 16.9% year-over-year to $100.4 million. A major catalyst is the $800+ million long-term edge AI agreement with Hanwha, signaling strong demand in physical AI markets. However, net income remains negative at -$117.13 million for 2025, though margins are improving.

Outlook: Wall Street is bullish with a $108.67 consensus price target (40% upside), driven by edge AI adoption and auto sector growth. Risks include persistent losses, competitive pressure from larger chipmakers, and execution challenges in scaling new AI contracts. The stock's valuation at 8.21x sales appears reasonable if revenue acceleration continues, but profitability remains key for sustained gains.

Medtronic (MDT) trades at $83.87, up 1.8% with a bullish technical signal and strong fundamental performance. The stock shows consistent earnings beats with Q1 2026 EPS of $1.55 exceeding expectations, while revenue growth accelerated to $33.54B in 2025. Analyst consensus remains strongly positive with 58% buy ratings and a $97.31 price target, representing 16% upside potential from current levels.

MDT presents an attractive investment case with solid profitability metrics, dividend aristocrat status, and accelerating revenue growth. Key risks include increasing debt levels (debt-to-asset ratio rose to 31.11% in 2025) and margin pressure from tariffs. The company's strategic acquisitions and innovation in cardiovascular and neuroscience segments support long-term growth prospects despite near-term headwinds.